Vistagen Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview

Vistagen Therapeutics

13/06/2025 21:10

Vistagen Therapeutics Inc VTGN.OQ VTGN.O is expected to show a rise in quarterly revenue when it reports  results on June 17 for the period ending March 31 2025

The South San Francisco California-based  company is expected to report a 59.9% increase in revenue to $315 thousand from $197 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Vistagen Therapeutics Inc is for a loss of 50 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $12.00‚Äč, above‚Äč its last closing price of $2.32. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.51
-0.51
-0.46
Beat
9.8
Sep. 30 2024
-0.39
-0.39
-0.42
Missed
-7.7
Jun. 30 2024
-0.41
-0.40
-0.35
Beat
13.6‚Äč
Mar. 31 2024
-0.33
-0.36
-0.25
Beat
31
‚Äč‚ÄčDec. 31 2023
-0.28
-0.30
-0.22
Beat
27.3
Sep. 30 2023
-0.68
-0.68
-0.66
Beat
2.9‚Äč
Mar. 31 2023
-1.50
-1.75
Missed
-16.7

This summary was machine generated June 13 at 20:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)